RecruitingPhase 1NCT07205926

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Safety and Immunogenicity of IVT Shigella-04 in Healthy Young Adults

Sponsor

Inventprise Inc.

Enrollment

60 participants

Start Date

Oct 9, 2025

Study Type

INTERVENTIONAL

Conditions

Diarrhea Shigella

Summary

Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults

Eligibility

Min Age: 18 YearsMax Age: 49 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called IVT Shigella-04 and a biological treatment called Placebo (0.9% saline) for people with diarrhea and shigella. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 49 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.